Found: 24
Select item for more details and to access through your institution.
Front Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. C1, doi. 10.1111/dom.15489
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO‐DKD and FIDELIO‐DKD.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 924, doi. 10.1111/dom.15387
- By:
- Publication type:
- Article
Effect of Extracellular ATP on Cisplatin-Induced Cytotoxicity in Human Ovarian Carcinoma Cells.
- Published in:
- Chemotherapy (0009-3157), 2010, v. 56, n. 1, p. 1, doi. 10.1159/000287351
- By:
- Publication type:
- Article
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2020, v. 50, n. 1, p. 1, doi. 10.1007/s11239-020-02073-z
- By:
- Publication type:
- Article
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2020, v. 50, n. 1, p. 12, doi. 10.1007/s11239-020-02078-8
- By:
- Publication type:
- Article
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 11, p. 1639, doi. 10.1007/s40262-023-01282-y
- By:
- Publication type:
- Article
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 439, doi. 10.1007/s40262-021-01082-2
- By:
- Publication type:
- Article
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
- Published in:
- Clinical Pharmacokinetics, 2021, v. 60, n. 11, p. 1407, doi. 10.1007/s40262-021-01024-y
- By:
- Publication type:
- Article
Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas Disease.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 10, p. 1273, doi. 10.1002/jcph.2064
- By:
- Publication type:
- Article
An Integrated Population Pharmacokinetic Analysis to Characterize Levonorgestrel Pharmacokinetics After Different Administration Routes.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 12, p. 1639, doi. 10.1002/jcph.1288
- By:
- Publication type:
- Article
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2019, v. 13, p. N.PAG, doi. 10.1177/1753944719863641
- By:
- Publication type:
- Article
Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1197, doi. 10.1111/cts.13523
- By:
- Publication type:
- Article
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1092, doi. 10.1002/cpt.3173
- By:
- Publication type:
- Article
NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 2, p. 498, doi. 10.1002/cpt.2222
- By:
- Publication type:
- Article
Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 5, p. 880, doi. 10.1002/psp4.13125
- By:
- Publication type:
- Article
Evaluation of covariate effects in item response theory models.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 5, p. 812, doi. 10.1002/psp4.13120
- By:
- Publication type:
- Article
Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 11, p. 1666, doi. 10.1002/psp4.13000
- By:
- Publication type:
- Article
Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 12, p. 894, doi. 10.1002/psp4.12464
- By:
- Publication type:
- Article
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 11, p. 805, doi. 10.1002/psp4.12444
- By:
- Publication type:
- Article
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2018, v. 7, n. 5, p. 309, doi. 10.1002/psp4.12288
- By:
- Publication type:
- Article